Investing in Medicine
Aescap invests in high-growth companies that develop and market highly innovative medicines.
Aescap 2.0 is a biotech fund that invests in publicly traded biotech companies. It invests in high-growth, highly innovative companies that develop and market new medicines and, to a lesser extent, diagnostics and/or medical devices. Aescap 2.0 has around 230 million euros under management and has had an annualized net performance of more than 19% over its five years of existence. Entry into and exit from this biotech fund is possible twice per month.
The biotech market is a large and fast-growing market where breakthrough medicines can be sold globally. The substantial growth of the biotech market, also called life sciences market, is driven by a longer life expectancy (especially in the emerging markets) as well as an ageing population. Both factors are driving demand for improved and cost-effective medicine, diagnostics and medical devices. There is also still a high unmet medical need for diseases like Alzheimer’s, Arthritis, Cancer, Diabetes, Multiple Sclerosis (MS), Obesity, Parkinson’s and many other diseases. Today for approximately 6,000 rare diseases there is still no cure or treatment at all available.